Shots:

• The P-III Archway study involves assessing of PDS with ranibizumab- refilled @6mos. at fixed intervals- vs ranibizumab (0.5mg- monthly IVT) in 418 patients with nAMD- prior treated with VEGF therapy
• Results: 98.4% of PDS patients were able to go 6mos. without needing additional treatment and achieved vision outcomes equivalent to patients receiving ranibizumab (0.5mg- monthly IVT)- PDS demonstrated non-inferior and equivalent visual acuity outcomes with a favorable benefit-risk profile
• PDS is a permanent refillable eye implant that continuously delivers a customized formulation of ranibizumab over a period of mos.- potentially reducing the treatment burden associated with frequent eye injections

  Ref: Genentech | Image: Twitter